1
|
Collier MA, Peine KJ, Gautam S, Oghumu S, Varikuti S, Borteh H, Papenfuss TL, Sataoskar AR, Bachelder EM, Ainslie KM. Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles. Int J Pharm 2016; 499:186-194. [PMID: 26768723 DOI: 10.1016/j.ijpharm.2016.01.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 12/29/2015] [Accepted: 01/04/2016] [Indexed: 12/15/2022]
Abstract
Leishmaniasis is a disease caused by parasites of Leishmania sp., which effects nearly 12 million people worldwide and is associated with treatment complications due to widespread parasite resistance toward pathogen-directed therapeutics. The current treatments for visceral leishmaniasis (VL), the systemic form of the disease, involve pathogen-mediated drugs and have long treatment regimens, increasing the risk of forming resistant strains. One way to limit emergence of resistant pathogens is through the use of host-mediated therapeutics. The host-mediated therapeutic AR-12, which is FDA IND-approved for cancer treatment, has shown activity against a broad spectrum of intracellular pathogens; however, due to hydrophobicity and toxicity, it is difficult to reach therapeutic doses. We have formulated AR-12 into microparticles (AR-12/MPs) using the novel biodegradable polymer acetalated dextran (Ace-DEX) and used this formulation for the systemic treatment of VL. Treatment with AR-12/MPs significantly reduced liver, spleen, and bone marrow parasite loads in infected mice, while combinatorial therapies with amphotericin B had an even more significant effect. Overall, AR-12/MPs offer a unique, host-mediated therapy that could significantly reduce the emergence of drug resistance in the treatment of VL.
Collapse
Affiliation(s)
- M A Collier
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - K J Peine
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - S Gautam
- Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States
| | - S Oghumu
- Department of Pathology, The Ohio State's Wexner Medical Center, The Ohio State University, Columbus, OH 43210, United States
| | - S Varikuti
- Department of Pathology, The Ohio State's Wexner Medical Center, The Ohio State University, Columbus, OH 43210, United States
| | - H Borteh
- Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States
| | - T L Papenfuss
- Department of Pathology, The Ohio State's Wexner Medical Center, The Ohio State University, Columbus, OH 43210, United States
| | - A R Sataoskar
- College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, United States
| | - E M Bachelder
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - K M Ainslie
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
| |
Collapse
|
2
|
Yasmeen R, Meyers JM, Alvarez CE, Thomas JL, Bonnegarde-Bernard A, Alder H, Papenfuss TL, Benson DM, Boyaka PN, Ziouzenkova O. Aldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations. Biochim Biophys Acta 2013; 1833:3218-3227. [PMID: 24080087 DOI: 10.1016/j.bbamcr.2013.09.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2013] [Revised: 09/18/2013] [Accepted: 09/19/2013] [Indexed: 12/11/2022]
Abstract
The deregulation of B cell differentiation has been shown to contribute to autoimmune disorders, hematological cancers, and aging. We provide evidence that the retinoic acid-producing enzyme aldehyde dehydrogenase 1a1 (Aldh1a1) is an oncogene suppressor in specific splenic IgG1(+)/CD19(-) and IgG1(+)/CD19(+) B cell populations. Aldh1a1 regulated transcription factors during B cell differentiation in a sequential manner: 1) retinoic acid receptor alpha (Rara) in IgG1(+)/CD19(-) and 2) zinc finger protein Zfp423 and peroxisome proliferator-activated receptor gamma (Pparg) in IgG1(+)/CD19(+) splenocytes. In Aldh1a1(-/-) mice, splenic IgG1(+)/CD19(-) and IgG1(+)/CD19(+) B cells acquired expression of proto-oncogenic genes c-Fos, c-Jun, and Hoxa10 that resulted in splenomegaly. Human multiple myeloma B cell lines also lack Aldh1a1 expression; however, ectopic Aldh1a1 expression rescued Rara and Znf423 expressions in these cells. Our data highlight a mechanism by which an enzyme involved in vitamin A metabolism can improve B cell resistance to oncogenesis.
Collapse
Affiliation(s)
- R Yasmeen
- Department of Human Sciences, The Ohio State University, Columbus, OH 43210, USA
| | - J M Meyers
- Department of Human Sciences, The Ohio State University, Columbus, OH 43210, USA
| | - C E Alvarez
- Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA
| | - J L Thomas
- Department of Human Sciences, The Ohio State University, Columbus, OH 43210, USA
| | - A Bonnegarde-Bernard
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
| | - H Alder
- Nucleic Acid Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - T L Papenfuss
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
| | - D M Benson
- Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - P N Boyaka
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
| | - O Ziouzenkova
- Department of Human Sciences, The Ohio State University, Columbus, OH 43210, USA.
| |
Collapse
|
3
|
Wasserman J, Diese L, VanGundy Z, London C, Carson WE, Papenfuss TL. Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells. Vet Immunol Immunopathol 2011; 145:420-30. [PMID: 22244518 DOI: 10.1016/j.vetimm.2011.12.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 12/19/2011] [Accepted: 12/21/2011] [Indexed: 01/05/2023]
Abstract
BACKGROUND Cancer profoundly affects immunity and causes immunosuppression that contributes to tumor escape, metastases and resistance to therapy. The mechanisms by which cancer cells influence immune cells are not fully known but both innate and adaptive immune cells can be altered by cancer. Myeloid cells are innate immune cells that comprise the mononuclear phagocytic system (MPS) and include monocytes, macrophages, dendritic cells (DCs) and their progenitors. Myeloid cells play important roles in both the promotion and regulation of immune responses. Dysregulated myeloid cells are increasingly being recognized as contributing to cancer-related immunosuppression. This study investigated whether soluble factors produced by canine tumor cells inhibited canine myeloid cell function. METHODS These studies investigated the utility of using the canine DH82 cell line for assessment of canine myeloid responses to tumor-derived soluble factors (TDSFs). Phenotypic comparisons to canine bone marrow-derived DCs (BM-DCs) and bone marrow-derived macrophages (BM-MΦs) were performed and expression of myeloid cell markers CD11b, CD11c, CD80, and major histocompatibility complex (MHC) class II were evaluated by flow cytometry. Phenotypic and functional changes of DC populations were then determined following exposure to tumor-conditioned media (TCM) from canine osteosarcoma, melanoma and mammary carcinoma cell lines. RESULTS We found that the canine BM-DCs and the DH82 cell line shared similar CD11b, CD11c and MHC II expression and morphologic characteristics that were distinct from canine BM-MΦs. Myeloid cells exposed to TDSFs showed decreased expression of MHC class II and CD80, had reduced phagocytic activity and suppressed the proliferation of responder immune cells. CONCLUSION These results show that soluble factors secreted from canine tumor cells suppress the activation and function of canine myeloid cells. Our results suggest that, similar to humans, dysregulated myeloid cells may contribute to immunosuppression in dogs with cancer.
Collapse
Affiliation(s)
- J Wasserman
- Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA
| | | | | | | | | | | |
Collapse
|
4
|
Gatson NN, Ji H, Gienapp IE, Song F, Papenfuss TL, Camps M, Ruckle T, Zimmerer JL, Shawler TM, Lu B, Gerard C, Kithcart AP, Powell N, Fischer AJ, Satoskar A, Rommel C, Whitacre CC. A distinct role for PI3Kgamma in suppressing the development and progression of experimental autoimmune encephalomyelitis (EAE) (129.30). The Journal of Immunology 2007. [DOI: 10.4049/jimmunol.178.supp.129.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Phosphoinositide 3-kinases (PI3K) are intracellular signaling proteins involved in cellular responses such as chemotaxis, proliferation and apoptosis. Selective inhibitors of the PI3Kγ-isoform have recently become available. This study explores the role of PI3Kγ in the development and progression of EAE. PI3Kγ +/+ (wt) and PI3Kγ −/− (ko) mice were immunized for EAE using myelin oligodendrocyte glycoprotein p35-55 (MOG) and assessed for clinical signs, CNS histopathology and T cell activation. WT mice showed a progressive disease course with elevations in inflammatory cytokines increased CNS mononuclear infiltrates. In contrast, ko mice exhibited a delayed onset and dramatically less severe EAE course characterized by decreased T cell activation and inflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-12p40, IL-6, IL-17 and MCP-1). Male ko mice were significantly more protected than ko females. Adoptive transfer of MOG-activated T cells into ko recipients show that ko mice are resistant to passive disease induction. Interestingly, wt recipients of ko donors immunized for EAE were also protected. Furthermore, adoptive transfer of activated GFP+ T cells show marked decreased infiltration of GFP+ T cells into the CNS. Taken together, these findingssuggest that depletion of PI3Kγ results in a down-regulation of the inflammatoryresponse caused by impaired trafficking of cells critical to generation of the immune response.
(Supported by NIH grant AI 064320 and National MS Society Grant RG 3272).
Collapse
Affiliation(s)
- NaTosha N Gatson
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - H Ji
- 2Merck Serono, Serono International SA, 15bis Chemin Des Mines, Geneva, Switzerland,
| | - I E Gienapp
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - F Song
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - T L Papenfuss
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - M Camps
- 2Merck Serono, Serono International SA, 15bis Chemin Des Mines, Geneva, Switzerland,
| | - T Ruckle
- 2Merck Serono, Serono International SA, 15bis Chemin Des Mines, Geneva, Switzerland,
| | - J L Zimmerer
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - T M Shawler
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - B Lu
- 3Children’s Hospital Harvard, 300 Longwood Ave., Boston, MA, 02115
| | - C Gerard
- 3Children’s Hospital Harvard, 300 Longwood Ave., Boston, MA, 02115
| | - A P Kithcart
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - N Powell
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - A J Fischer
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - A Satoskar
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| | - C Rommel
- 2Merck Serono, Serono International SA, 15bis Chemin Des Mines, Geneva, Switzerland,
| | - C C Whitacre
- 1MVIMG, The Ohio State University, 460W 12th Ave, BRT Rm 760, Columbus, OH, 43210,
| |
Collapse
|